Fierce JPM Week: As Novartis tries to avoid 'me-too' meds in M&A hunt, R&D chief urges biotechs to 'please reach out' Fierce JPM Week: Confidence is high for Eli Lilly CEO Ricks in showdown with Biogen's Aduhelm Bloodletting at Zymeworks as new CEO axes half of senior leaders, plans 25% reduction in headcount Sponsored: Engineering Biology: The Evolution of the Biopharma Industry Fierce JPM Week: Johnson & Johnson's JLABS—Taming the beast, while letting it roam the world Fierce JPM Week: Sage wants to 'raise the bar' on depression meds with quick start zuranolone Eleusis joins cooled-off SPAC market with $288M to bankroll psychedelic-based depression drug Novartis-backed ImmPACT Bio snags $111M and new CEO as cancer CAR-T yields phase 1 results Fresh from $86M series A, Metis poaches Kala CSO to support move into the clinic Fierce JPM Week: Game recognizes game—Lilly, Novartis execs commend Pfizer on Paxlovid, but where does that leave them in the COVID market? Stop sugarcoating cancer cells to empower CAR-T therapy in solid tumors CROs embracing tech to decentralize trials and speed enrollment as regulators show support 'with their feet' Gilead says counterfeiters sold $250M worth of fake HIV drugs, sues distributors Biden confident he can get 'big chunks' of $1.75T Build Back Better Act signed into law Featured Story | By Annalee Armstrong At the end of Jay Bradner’s interview for Fierce JPM Week, the Novartis innovation chief turned to the camera and implored small biotechs to get in touch to talk M&A or potential partnerships. read more |
| |
|---|
|
Top Stories By Annalee Armstrong Eli Lilly is so serious about becoming the leader in Alzheimer’s disease with donanemab that the Indianapolis Big Pharma challenged competitor Biogen to a head-to-head trial for their two therapies last year. read more By Nick Paul Taylor Kenneth Galbraith has made an immediate mark on Zymeworks. Days after taking up the CEO position, Galbraith has axed half the senior management team and disclosed plans to cut total headcount by 25%. read more Sponsored by: Danaher Corporation Is biopharma ready to reap the rewards and realize the full potential of synthetic/engineering biology? Jennifer Honeycutt talks about how engineering biology with the right partners could provide new pathways to drug discovery and development, portable cell-free solutions for scalable industrial biomanufacturing on demand, and new preclinical testing methods for better science and smarter biopharma. read more By Ben Adams JLABS has grown into a massive organization that spans the globe and is helping big ideas from small beginnings get off the ground. read more By Kyle LaHucik Existing meds haven't delivered on treating the depression that impacts millions of Americans. That's how Sage Therapeutics sees it, and with partner Biogen, the biopharma thinks it can "raise the bar" for patients and healthcare providers. read more By Kyle LaHucik With investor interest in psychedelics heating up, Eleusis joins the relatively quiet SPAC market in a deal that gives the biotech $288 million to test a psilocybin-based treatment for depression. The proceeds will also bankroll an expansion of subsidiary Andala's drug therapy clinics. read more By Kyle LaHucik ImmPACT Bio raised $111 million in series B funds to bankroll development of three CAR-T treatments, including a phase 1 drug that led to complete remission in seven of eight patients treated to date. The California biotech also named ex-Pfizer SVP and Baxter President Sumant Ramachandra as its CEO. read more By Nick Paul Taylor Hongming Chen has ended her long affiliation with Kala Pharmaceuticals. Having been with Kala since its origins in 2010, Chen has left the chief scientific officer post to become head of R&D at a biotech that is just starting out. read more By Annalee Armstrong It’s not often that high profile pharmaceutical executives publicly laud a direct competitor’s medicine, but that’s what’s happening these days for Pfizer’s COVID-19 antiviral Paxlovid. read more By Angus Liu To repeat the success of CAR-T therapies in blood cancers, a key direction for solid tumor research focuses on enabling the engineered immune cells to better target those tumors. Now, a group of scientists in Italy have proposed a method to do just that by breaking down a sugar-based shield around cancer cells. read more By Gareth Macdonald Demand for faster enrollment and growing use of decentralized trials model are increasing use of management tech in clinical development, according to Florence Healthcare. read more By Kevin Dunleavy Gilead sued a network of drug distributors, claiming they endangered patients by selling more than $250 million in counterfeit versions of the company’s HIV drugs—mostly Biktarvy and Descovy—in the United States over the last two years. read more By Robert King President Joe Biden endorsed splitting up his $1.75 trillion Build Back Better Act, but it remains unclear what healthcare policies could survive such a piecemeal approach. read more Resources Sponsored by: WIRB-Copernicus Group Sites receiving augmentation support enroll more than 30,000 patients in just over three months. See how additional site resources can make a difference. Sponsored by: Thermo Fisher Scientific Learn how a CDMO partnered with Thermo Fisher Scientific to manage high-volume process liquid and buffer preparation scale-up. Download the free case study from Thermo Fisher Scientific Sponsored by: Thermo Fisher Scientific A variety of genetic analysis methods are valuable in ensuring that ex vivo human cells to be used for cell-based therapies are correctly identified, have the correct characteristics, and are free of contaminants. Sponsored by: IQVIA Learn how to elevate your omnichannel marketing strategy with Next Best - a combination of data and analytics, deployed to facilitate decision making. Sponsored by: Catalent Biologics Ypsomed and Catalent Biologics experts discuss strategies for integrated PFS manufacturing and auto-injector assembly to accelerate timelines and more in this webinar. Sponsored by: Catalent Biologics Learn how formulation development for a PFS affects manufacturing to drive the industry toward optimizing delivery of injectable products and, ultimately, improving patient care. Sponsored by: Thermo Fisher Scientific Learn how to develop a high-performing supply chain for cGMP chemicals used throughout your biologics workflow. Download the free whitepaper from Thermo Fisher Scientific Sponsored by: Box Read Get to Know Cloud Content Management for Life Sciences and learn how to eliminate silos across all workflows, from R&D to commercialization. Immuno-Oncology 360° Summit March 16-18, 2022 | New York Marriott Brooklyn Bridge Fierce JPM Week 2022 January 18-20, 2022 | Virtual Event Fierce Drug Safety Summit February 8-9, 2022 | Arlington, VA | Presented by Fierce Pharma
February 16-17, 2022 | Virtual Fierce BD&L Summit for Life Sciences March 2022 | San Francisco, CA Fierce Promotional Review Committee Compliance and Best Practices Summit April 12-14, 2022 | New Brunswick, NJ Fierce Medical Affairs Strategic Summit (MASS) East April 12-14, 2022 | New Brunswick, NJ Fierce Health IT Summit April 20, 2022 | Virtual Event Fierce Trial Master File Summit May 2-4, 2022 | New Orleans, LA & Streaming Live Fierce Leaders in Life Sciences Summit May 16-17, 2022 | Boston, MA Fierce Digital Pharma Innovation Week June 21-23, 2022 | Virtual Event Fierce Biotech Next-Gen June 29, 2022 | Virtual Event Fierce Pharma PR & Communications Summit July 2022 | Location TBD (NYC Metro Area) Fierce Biotech Forum October 2022 | Location TBD Fierce Pharma Meeting Professionals Summit November 2-3, 2022 | Atlantic City, NJ Fierce European Trial Master File Summit November 2022 | Location TBD | 